BellaSeno pivotal trial enrols 30 women for absorbable breast scaffold
BellaSeno has announced that 30 women across two clinical studies have now received its absorbable polycaprolactone breast scaffold, as the company advances into a pivotal trial launched in January 2026. The milestone follows the completion of a first-in-human safety study involving 19 patients between 2021 and 2023, two-year outcomes from which were presented at The Aesthetic MEET 2026 in Boston in May.
The scaffold is inserted into the breast and seeded with the patient's own adipose tissue. It acts as a structural framework that supports tissue ingrowth while gradually resorbing over one to two years. Polycaprolactone, the material used, has an established safety record in absorbable surgical sutures, and BellaSeno says no scaffold-related complications were observed in the safety cohort. These included the absence of capsular contracture, infection, necrosis, calcification, oil cysts, or scaffold removals. Patient-reported satisfaction was high, and the study recorded 83 per cent mean breast volume retention at two years.
Trial progress and near-term milestones
The active pivotal trial, running in Australia under principal investigators Professor Owen Ung and Professor Anand Deva, had enrolled 11 patients for scaffold surgery at the time of the announcement, with more already scheduled. BellaSeno expects total enrolment across both trials to exceed 60 patients by the end of August 2026.
Professor Deva described the MRI appearances of treated tissue as indistinguishable from normal breast parenchyma. He said the results represented "the most significant advancement we have seen in the field of breast surgery for decades," though The Biotech Times notes this characterisation comes from a named principal investigator who has a professional stake in the programme's success.
Dr Mohit Chhaya, co-founder and chief executive, said the company was beginning to consider a commercialisation pathway following the evidence-building phase. No regulatory submission timeline or target jurisdiction was disclosed in the release.
Market context and competitive landscape
The breast reconstruction and augmentation device market is substantial. Silicone and saline implants remain the dominant surgical approach globally, but the category has faced scrutiny over links to breast implant-associated anaplastic large cell lymphoma and, more recently, breast implant illness. Regulatory bodies including the US Food and Drug Administration and the European Medicines Agency have tightened labelling and surveillance requirements for implant manufacturers in recent years, creating an environment in which a fully absorbable, autologous-tissue-supporting alternative could attract both clinical and regulatory interest.
BellaSeno is not the only company pursuing scaffold-based soft tissue restoration. A number of academic and commercial groups are investigating synthetic and biologic scaffold matrices for breast reconstruction, particularly in the post-mastectomy setting. What distinguishes BellaSeno's published data at this stage is the two-year safety readout with no scaffold-related complications and the quantified volume retention figure, both of which are meaningful for surgeons weighing risk in an elective or reconstructive context.
The pivotal trial's eventual dataset, covering efficacy, safety and longer-term outcomes, will be the critical determinant of any regulatory approval strategy. Investors and acquirers in the reconstructive device space will be watching for the full pivotal readout and for clarity on whether BellaSeno intends to seek CE Mark, FDA 510(k) or De Novo, or premarket approval, each of which carries materially different evidence requirements and timelines.